Clinical Trial Update: Metabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 Inhibitors [Phase 4]

View source ↗

Summary

Phase 4 study evaluating metabolic and renal outcomes in cardiac surgery patients treated with SGLT2 inhibitors. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury

Drugs mentioned

• FARXIGA (dapagliflozin)
• INVOKANA (CANAGLIFLOZIN)
• Jardiance (empagliflozin)
• STEGLATRO (ertugliflozin)

Snippet

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Conditions: Acute Kidney Injury | Phase 4 | Status: COMPLETED